Fujirebio US Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Fujirebio US's estimated annual revenue is currently $93.6M per year.(i)
  • Fujirebio US's estimated revenue per employee is $251,000

Employee Data

  • Fujirebio US has 373 Employees.(i)
  • Fujirebio US grew their employee count by 6% last year.

Fujirebio US's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
Director, Manufacturing OperationsReveal Email/Phone
3
Director Finance and AccountingReveal Email/Phone
4
Sr. Director, Clinical and Regulatory ScienceReveal Email/Phone
5
Director Quality AssuranceReveal Email/Phone
6
Director, Materials ManagementReveal Email/Phone
7
Director, Global OEM Business PlanningReveal Email/Phone
8
Director Technical ManufacturingReveal Email/Phone
9
Director EngineeringReveal Email/Phone
10
Sr. Clinical Market Development ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$73.5M29312%N/AN/A
#2
$7M28-10%N/AN/A
#3
$37.9M15113%N/AN/A
#4
$2.1M17-78%$64.3MN/A
#5
$9.3M37-10%N/AN/A
#6
$56.2M1790%N/AN/A
#7
$38.9M155-1%N/AN/A
#8
$22.1M885%N/AN/A
#9
$22.1M889%N/AN/A
#10
$33.4M13310%N/AN/A
Add Company

What Is Fujirebio US?

Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD). It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Fujirebio is today a member of Miraca Group (Miraca Holdings Inc. listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1.200 people in Asia, Europe and America.

keywords:N/A

N/A

Total Funding

373

Number of Employees

$93.6M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Fujirebio US News

2022-04-20 - Syphilis Immunoassay Diagnostics Market Size, Scope And ...

New Jersey, United States – The study is a professional and comprehensive ... Abbott Laboratories, Ortho Clinical Diagnostics, Fujirebio (Miraca Group),...

2022-04-19 - Tropical Spastic Paraparesis Diagnosis Market 2022 ...

California (United States) – The Tropical Spastic Paraparesis Diagnosis Market ... MP Biomedicals, Fujirebio, Inc., Quest Diagnostics,...

2022-04-19 - Cytology and HPV Testing Market Size, Outlook And Forecast ...

New Jersey, United States – The Cytology and HPV Testing Market ... Abbott, Arbor Vita, Becton Dickinson, Cepheid, Roche, Fujirebio,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$123.4M395N/AN/A
#2
$146.8M4057%N/A
#3
$83.3M40930%N/A
#4
$15M41217%N/A
#5
$163.5M4515%N/A